In the 1990s, HIV went from a death sentence to a manageable chronic condition. The change came mostly from combination antiretroviral therapy, which pushes the virus down to undetectable levels in the blood. That treatment means daily pills, and daily pills taken for a lifetime are hard to keep up. A phase 3 trial in the New England Journal of Medicine tests a two-drug combination taken by mouth once a week, which could lighten that load a great deal.
HIV, the human immunodeficiency virus, attacks CD4 T cells, which act as coordinators of the immune response. Without treatment, the virus slowly wears them down until the person has AIDS. At that point infections and cancers that a healthy immune system would hold in check become life-threatening.
Antiretroviral drugs block the virus at different steps of its life cycle. Some stop it entering cells. Some stop it copying its genetic material once inside. Some block the last step, where new virus particles are assembled and released.
Using one drug at a time fails, and that lesson was learned the hard way. HIV copies itself at an enormous rate and mutates quickly, so any single drug soon faces a virus population that has evolved around it. Two or three drugs from different classes at once make it far harder for the virus to find mutations that beat all of them together. That combination approach drove the virus below detection in most patients and has kept it there for decades.
For most people on treatment, the drugs work very well. The weak point is taking a pill every day for life. Missed doses let the virus multiply again, which can breed resistance. Some patients feel the stigma of carrying daily medication. Side effects from long-term pills, though far milder than in the early years, still affect some people. And in much of the world, a steady daily supply of pills is not reliable because health systems have gaps. All of this drives the push toward less frequent dosing.
Long-acting injections already exist. Cabotegravir plus rilpivirine, injected every one or two months, works very well and is approved in several countries. But injections need clinic visits, trained staff to give them, and cold storage. A pill taken once a week avoids all of that. It can come from a pharmacy and be taken at home, which helps where clinics are stretched. For many patients around the world, a weekly pill may be more practical than a monthly shot, even though the shot lasts longer.
Islatravir had a rocky start. In an earlier program it was paired with a different drug, and some of those trials were stopped when investigators saw unexpected drops in CD4 T cell counts. Since CD4 cells are the very cells HIV attacks, losing them while the virus was under control was worrying.
The cause was traced. Islatravir gets built into the DNA of dividing cells, including CD4 cells, and at higher concentrations it seemed to slow their growth. The dose in that earlier program was likely too high. The program was redesigned with a lower dose and a new partner, lenacapavir, whose way of working lets the islatravir dose come down while the combination still controls the virus. This trial is the product of that redesign, and one thing it tests is whether the CD4 problem returns at the lower dose.
So the story is not simply two new drugs combined. It is a drug with a difficult history, reworked. Publication in this journal with a successful main result suggests the CD4 concern did not come back at the lower dose, but only the full safety data can show whether that is true and how sure we can be.
Think of the virus as needing to photocopy its genetic instructions inside a cell. The older backbone drugs of HIV treatment jam the copying machine, the enzyme called reverse transcriptase. Islatravir jams a slightly different step of that same copying process. That gives it a different pattern of resistance from the older drugs, which is scientifically valuable. It also lingers inside cells for a long time, long enough to cover a whole week. That is what makes weekly dosing possible.
Lenacapavir works on something else entirely: the capsid, the protein shell that wraps the virus's genetic material inside the cell. It was the first drug of its kind to be approved. By grabbing onto that shell, it disrupts several steps: how the virus gets into the cell's nucleus, how new virus particles are built, and how they mature. No other approved drug class targets this part of the virus, so its resistance pattern differs from every existing HIV drug. It was first approved as an injection every six months for people whose HIV resists many other drugs. This trial extends it to a weekly pill.
What follows is based on the published abstract. The trial compared weekly oral islatravir plus lenacapavir with a standard daily regimen in adults with HIV-1. The main measure was viral suppression at a set time point: the share of participants whose virus was below the level tests can detect. The trial met that goal, showing the weekly combination was at least as good as daily treatment. Peer review at the New England Journal of Medicine found the evidence credible and the design rigorous.
A phase 3 randomized trial in HIV is a high bar of evidence. Viral suppression is the right thing to measure, because it is what prevents both disease progression and passing the virus on. Earlier phase 3 trials of long-acting injections used the same measure, so the framework is well established.
What the abstract does not reveal matters too. It does not give the exact suppression rates in each group, the full list of side effects, or what happened to resistance in the small number of people whose virus came back. Those details decide how close this comes to the best daily regimens.
Any long-acting drug raises a question about missed doses. Picture the drug level after the last dose as a tide going out slowly. On the way down, there is a stretch where enough drug remains to pressure the virus toward resistance, but not enough to fully suppress it. Daily pills clear quickly, so that stretch is short. Weekly or monthly drugs leave a longer one. Whether the length of this combination's fade, plus the resistance barriers of both drugs, keeps that risk low is something the trial data and its resistance analysis will have to show.
Early use would likely go to people already stably controlled on daily pills who want something simpler, and to people known to struggle with daily pills. The global picture differs from that in wealthy countries. Where cheap generic daily pills are available, a weekly branded combination would need affordable pricing or generic licensing to matter at scale. Whether a drug works and whether people can get it are separate questions, and global HIV treatment is as much a political and economic problem as a scientific one.
A simpler pill helps at the margins, but pill design is usually not the bottleneck. The two biggest barriers worldwide are testing, so people know their status, and linkage to care, getting diagnosed people into treatment and keeping them there. A weekly pill solves neither. It may help people already in care who struggle with daily pills, and ease the load on systems that spend heavily on clinic visits for injections.
The trial ran in several countries, which makes the results more likely to hold worldwide than a single-country study. HIV is concentrated in sub-Saharan Africa, South Asia and other regions long underrepresented in trials run mainly in wealthy countries. Including sites in high-burden regions gives data closer to real patient populations, which matters for approval in those regions and for negotiating access.
This fits a wider pattern in medicine: the best drug is the one the patient actually takes. Fewer doses is one of the most reliable ways to improve adherence, and adherence decides outcomes in chronic disease. Once-daily blood pressure pills replaced three-times-daily ones. Monthly osteoporosis drugs replaced daily ones. A weekly HIV combination follows the same path.
The long-acting HIV options now form a menu. The monthly cabotegravir-rilpivirine injection suits people who can reach a clinic and would rather not think about pills. The six-monthly lenacapavir injection is reserved for people with extensive drug resistance. This weekly pill sits in the middle: infrequent dosing with the ease of taking it at home. That range lets patients in different circumstances find what fits.
The paper is PMID 42525925, published in the New England Journal of Medicine on July 29, 2026. This account is based on the published abstract; the full text is behind a paywall.